Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib with Trastuzumab and Capecitabine in HER2+ Early Breast Cancer
NCT05292742Phase 2Recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Jul 2021
- Primary completion
- Oct 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pyrotinib in breast cancer (2 arms), sponsored by Fujian Medical University Union Hospital. Primary endpoint: Invasive Disease-Free Survival at 3 years. Started Jul 2021; status: recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05292742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05292742.